Table 1.
Baseline characteristics according to KRAS mutation status
| Characteristics | No. of patients | KRAS | ||
|---|---|---|---|---|
| wild-type | mutant | p-value | ||
| (n = 82) | (n = 51) | (n = 31) | ||
| Age, year, Median (range) | 55.8 (25–77) | 58.8 (25–77) | 55.5 (29–77) | 0.565 |
| ≥65 years | 17 (21 %) | 12 (24 %) | 5 (16 %) | 0.423 |
| Sex | 0.867 | |||
| Male | 44 (54 %) | 27 (53 %) | 17 (55 %) | |
| Female | 38 (46 %) | 24 (47 %) | 14 (45 %) | |
| Location | 0.246 | |||
| Colon | 54 (66 %) | 36 (71 %) | 18 (58 %) | |
| Rectum | 28 (34 %) | 15 (29 %) | 13 (42 %) | |
| Neoadjuvant Chemotherapy | 21 (26 %) | 11 (22 %) | 10 (32 %) | 0.282 |
| Resection site | 0.039 | |||
| Liver | 57 (69 %) | 39 (76 %) | 18 (58 %) | |
| Lung | 13 (16 %) | 4 (8 %) | 9 (29 %) | |
| Others (ovary, bladder) | 12 (15 %) | 8 (16 %) | 4 (13 %) | |
| Tumor grade | 0.432 | |||
| Well | 10 (12 %) | 7 (14 %) | 3 (10 %) | |
| Moderate/Poor | 72 (78 %) | 44 (86 %) | 28 (90 %) | |
| T stage | 0.265 | |||
| T1 | 1 (1 %) | 1 (2 %) | 0 (0 %) | |
| T2 | 2 (2 %) | 2 (4 %) | 0 (0 %) | |
| T3 | 47 (57 %) | 30 (59 %) | 17 (55 %) | |
| T4 | 30 (37 %) | 18 (35 %) | 12 (39 %) | |
| Tx | 2 (2 %) | 0 (0 %) | 2 (6 %) | |
| N stage | 0.824 | |||
| N0 | 12 (15 %) | 8 (16 %) | 4 (13 %) | |
| N1 | 31 (38 %) | 18 (35 %) | 13 (42 %) | |
| N2 | 39 (47 %) | 25 (49 %) | 14 (45 %) | |
| 1st Adjuvant Chemo-Regimen | 0.923 | |||
| Oxaliplatin-based | 70 (86 %) | 44 (86 %) | 26 (84 %) | |
| Irinotecan-based | 10 (12 %) | 6 (12 %) | 4 (13 %) | |
| Only 5-FU | 2 (2 %) | 1 (2 %) | 1 (3 %) | |
| Use of Cetuximab at 1st post-operative chemotherapy | 4 (5 %) | 4 (8 %) | 0 (0 %) | NA |
| Use of Becavizumab at 1st post-operativechemotherapy | 13 (16 %) | 6 (12 %) | 7 (23 %) | 0.194 |
| Ever use of Cetuximab | 16 (20 %) | 16 (31 %) | 0 (0 %) | NA |
| Ever use of Bevacizumab | 23 (28 %) | 10 (20 %) | 13 (42 %) | 0.029 |
| Recurrence pattern (n = 57) | 0.616 | |||
| Primary site | 3 (5 %) | 1 (2 %) | 2 (8 %) | |
| Metastasectomy site | 27 (47 %) | 15 (46 %) | 12 (50 %) | |
| New distant sites | 27 (47 %) | 17 (52 %) | 10 (42 %) | |
| Duration of follow up month, median (range) | 25 (4–74) | 25 (4–74) | 34 (9–63) | 0.763 |
Abbreviations: CI confidence interval, A.A amino acid